Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Sinovac Biotech has announced that the company's pandemic influenza H5N1 whole viron inactivated vaccine, Panflu, has been granted a production license by the China State Food and Drug Administration.
Subscribe to our email newsletter
Panflu is claimed to be the first and only approved vaccine available in China against the H5N1 influenza virus. The vaccine is approved for production solely to be supplied to the Chinese national vaccine stockpiling program and will not be sold directly to the market. The license also indicates that the Chinese government has the exclusive right to initiate Panflu vaccinations in an emergency or in the event of an influenza pandemic.
Weidong Yin, chairman, president and CEO of Sinovac, said: “The government of China has indicated publicly their intention to stockpile the vaccine in advance of the Olympic games in Beijing this summer. Sinovac is committed to working closely with the regulators and the government to develop and implement the national stockpiling program for the pandemic influenza vaccine.”